Vaping Companies Are Thumbing Their Noses At FDA Rules And Getting Away With It

The Food and Drug Administration is determined to crack down on businesses that sell vaping products without its approval since e-cigarettes and e-liquids that contain nicotine have been considered a prescription-only medicine since 2021, reported STAT. However, many businesses are still making and selling illicit goods, thus ignoring FDA orders.

Moreover, defining the FDA’s demands seems to be a trend, with smoke shops and online retailers leading the way, despite facing seven-figure fines and removal of its products from shelves. Still, the FDA continues to refrain from taking action.

“FDA has been a toothless tiger that the industry isn’t afraid to ignore,” said Matt Myers, president of the Campaign for Tobacco-Free Kids.

To that end, there are signals that the agency may change the approach to the issue.

“The agency is currently working on further enforcement in situations where companies that have [been banned from the market] continue to sell illegal products,” the spokesperson wrote in an email to STAT. “The FDA is currently engaged in discussions with the Department of Justice (DOJ) regarding specific potential enforcement actions.”

FDA’s Rules Are Not Clear

On the other hand, vape shops justify their actions by arguing that the agency’s rules are not clear enough.

“There’s a complete lack of clarity or transparency from the agency to piece together what products are still legally able to be sold,” Amanda Wheeler, the president of the American Vapor Manufacturers said. “It would be legally and morally irresponsible for us to recommend that companies should voluntarily close down their businesses because FDA cannot sort out their filing systems.”

Meanwhile, the deadline for the companies to apply for FDA’s permission to sell vaping products was September 2020. In the years leading to that date, the vaping industry has grown into a $6 billion industry selling products without the agency’s approval.

For example, Juul Labs Inc., a producer of e-cigarettes, is a $15 billion enterprise with a 1,500-person workforce that started as a small, 200-person company. However, in June, the agency announced that it has banned the sale of Juul e-cigarettes in the U.S., reported CNBC. Even though the company has asked for the FDA’s approval for its vaping device and tobacco earlier, the agency said that the data provided by Juul are insufficient or conflicting in regards to the products’ use.

“Without the data needed to determine relevant health risks, the FDA is issuing these marketing denial orders,” Michele Mital, acting director of the FDA’s Center for Tobacco Products said in a statement.

Photo: Courtesy of Chiara Summer on Unsplash

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisGovernmentNewsRegulationsEntrepreneurshipFDAMarketsGeneralThe Food and Drug AdministrationVaping
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!


Loading...